Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. 2006

Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. a.schaefer@medizin.uni-wuerzburg.de

OBJECTIVE Platelet activation significantly contributes to cardiovascular morbidity and mortality in diabetes. An association between impaired NO-mediated platelet inhibition and platelet activation has recently been demonstrated in experimental diabetes. Guanylyl cyclase activation enhances the reduced signaling via the NO/cGMP pathway. We investigated whether chronic guanylyl cyclase activation would beneficially modulate platelet activation in experimental diabetes mellitus. RESULTS Diabetes was induced by streptozotocin-injection in male Wistar rats. After 2 weeks, treatment with either placebo or the guanylyl cyclase activator HMR1766 (10 mg/kg twice daily by gavage) was initiated. Two weeks later, in vivo platelet activation and in vitro platelet reactivity were assessed. Chronic treatment with HMR1766 enhanced NO/cGMP-mediated signaling in platelets from diabetic rats determined by in vivo phosphorylation of platelet vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. In parallel, platelet-binding of fibrinogen, surface-expression of P-selectin, appearance of platelet-derived microparticles, and platelet-aggregates with other blood cells were significantly reduced by chronic treatment with HMR1766. CONCLUSIONS Chronic activation of soluble guanylyl cyclase in diabetic rats improved markers of platelet activation and is a rationale approach for prevention of adverse cardiovascular events in diabetes.

UI MeSH Term Description Entries
D008297 Male Males
D008840 Microfilament Proteins Monomeric subunits of primarily globular ACTIN and found in the cytoplasmic matrix of almost all cells. They are often associated with microtubules and may play a role in cytoskeletal function and/or mediate movement of the cell or the organelles within the cell. Actin Binding Protein,Actin-Binding Protein,Actin-Binding Proteins,Microfilament Protein,Actin Binding Proteins,Binding Protein, Actin,Protein, Actin Binding,Protein, Actin-Binding,Protein, Microfilament,Proteins, Actin-Binding,Proteins, Microfilament
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010750 Phosphoproteins Phosphoprotein
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006162 Guanylate Cyclase An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2. Guanyl Cyclase,Deoxyguanylate Cyclase,Guanylyl Cyclase,Inosinate Cyclase,Cyclase, Deoxyguanylate,Cyclase, Guanyl,Cyclase, Guanylate,Cyclase, Guanylyl,Cyclase, Inosinate

Related Publications

Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
September 2011, Blood,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
April 1994, Annals of the New York Academy of Sciences,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
November 2006, The Journal of pharmacology and experimental therapeutics,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
November 1992, Naunyn-Schmiedeberg's archives of pharmacology,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
January 2000, Nihon rinsho. Japanese journal of clinical medicine,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
June 2022, British journal of pharmacology,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
October 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
October 2003, Vascular pharmacology,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
December 2009, British journal of pharmacology,
Andreas Schäfer, and Ulrike Flierl, and Anna Kobsar, and Martin Eigenthaler, and Georg Ertl, and Johann Bauersachs
January 2023, Nephron,
Copied contents to your clipboard!